Pallas Capital Advisors LLC Takes Position in Illumina, Inc. $ILMN

Key Points

• Pallas Capital Advisors acquired 25,513 Illumina shares in the second quarter, valued at approximately $4.49 million. Institutional investors and hedge funds collectively own 89.42% of the company.
• Illumina reported quarterly earnings of $1.31 per share, exceeding estimates of $1.23, while revenue rose 9.4% year over year to $1.16 billion. The company issued fiscal 2026 EPS guidance of $5.30–$5.40.
• Analyst sentiment remains mixed, with the stock carrying an average “Hold” rating and a consensus price target of $188.40. Meanwhile, insiders sold about 1.42 million shares worth $256 million over the past three months.

Pallas Capital Advisors LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,513 shares of the life sciences company's stock, valued at approximately $4,486,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Elyxium Wealth LLC acquired a new stake in Illumina during the fourth quarter worth approximately $25,000. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina in the 4th quarter valued at $26,000. Laurel Wealth Advisors LLC purchased a new position in shares of Illumina in the 4th quarter valued at $26,000. Activest Wealth Management raised its stake in Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after acquiring an additional 215 shares in the last quarter. Finally, Quarry LP purchased a new stake in Illumina in the third quarter valued at $32,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Keith A. Meister sold 283,269 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $199.61, for a total value of $56,543,325.09. Following the completion of the sale, the director directly owned 2,089,425 shares of the company's stock, valued at $417,070,124.25. This trade represents a 11.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares in the company, valued at approximately $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,415,351 shares of company stock worth $255,966,311 in the last three months. 2.90% of the stock is currently owned by company insiders.

Illumina Stock Performance

NASDAQ ILMN opened at $193.13 on Tuesday. The firm has a market cap of $29.16 billion, a P/E ratio of 36.03, a P/E/G ratio of 2.69 and a beta of 1.45. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The business's 50-day moving average price is $184.48 and its 200 day moving average price is $150.83. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company's revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on ILMN. Zacks Research raised Illumina from a "hold" rating to a "strong-buy" rating in a report on Monday, August 3rd. TD Cowen upped their target price on Illumina from $192.00 to $210.00 and gave the company a "hold" rating in a research report on Friday, July 31st. Weiss Ratings upgraded Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, June 3rd. Daiwa Securities Group raised Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 price target on the stock in a research report on Thursday, May 14th. Finally, Wall Street Zen raised Illumina from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $188.40.

Illumina Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source